Online inquiry

IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9904MR)

This product GTTS-WQ9904MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9904MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7402MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ2393MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ15700MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ8515MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ13283MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ14774MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ7293MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ13916MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN2477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW